Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.
Ebolaviruses are causative agents of lethal hemorrhagic fever in humans and nonhuman primates. Among the filoviruses characterized thus far, Reston Ebola virus (REBOV) is the only Ebola virus that is nonpathogenic to humans despite the fact that REBOV can cause lethal disease in nonhuman primates. Previous studies also suggest that REBOV is less effective at inhibiting host innate immune responses than Zaire Ebola virus (ZEBOV) or Marburg virus. Virally encoded VP35 protein is critical for immune suppression, but an understanding of the relative contributions of VP35 proteins from REBOV and other filoviruses is currently lacking. In order to address this question, we characterized the REBOV VP35 interferon inhibitory domain (IID) using structural, biochemical, and virological studies. These studies reveal differences in double-stranded RNA binding and interferon inhibition between the two species. These observed differences are likely due to increased stability and loss of flexibility in REBOV VP35 IID, as demonstrated by thermal shift stability assays. Consistent with this finding, the 1.71-A crystal structure of REBOV VP35 IID reveals that it is highly similar to that of ZEBOV VP35 IID, with an overall backbone r.m.s.d. of 0.64 A, but contains an additional helical element at the linker between the two subdomains of VP35 IID. Mutations near the linker, including swapping sequences between REBOV and ZEBOV, reveal that the linker sequence has limited tolerance for variability. Together with the previously solved ligand-free and double-stranded-RNA-bound forms of ZEBOV VP35 IID structures, our current studies on REBOV VP35 IID reinforce the importance of VP35 in immune suppression. Functional differences observed between REBOV and ZEBOV VP35 proteins may contribute to observed differences in pathogenicity, but these are unlikely to be the major determinant. However, the high level of similarity in structure and the low tolerance for sequence variability, coupled with the multiple critical roles played by Ebola virus VP35 proteins, highlight the viability of VP35 as a potential target for therapeutic development.
Leung
Daisy W
DW
Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA 50011, USA.
Shabman
Reed S
RS
Farahbakhsh
Mina
M
Prins
Kathleen C
KC
Borek
Dominika M
DM
Wang
Tianjiao
T
Mühlberger
Elke
E
Basler
Christopher F
CF
Amarasinghe
Gaya K
GK
D000595:Amino Acid Sequence; D018360:Crystallography, X-Ray; D029043:Ebolavirus / Q000737:chemistry*; D016899:Interferon-beta / Q000037:antagonists & inhibitors* / Q000235:genetics; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D055550:Protein Stability; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D012330:RNA, Double-Stranded / Q000737:chemistry; D012367:RNA, Viral / Q000737:chemistry; D054334:Viral Regulatory and Accessory Proteins / Q000737:chemistry* / Q000235:genetics
D012330:RNA, Double-Stranded; D012367:RNA, Viral; C080980:VP35 protein, filovirus; D054334:Viral Regulatory and Accessory Proteins; D016899:Interferon-beta
Wkly Epidemiol Rec. 2009 Feb 13;84(7):49-50
19219963
J Virol. 2009 Sep;83(17):8993-7
19515768
Methods Enzymol. 1997;276:307-26
27754618
Anal Biochem. 2006 Oct 15;357(2):289-98
16962548
J Virol. 2009 Apr;83(7):3069-77
19153231
Adv Virus Res. 1996;47:1-52
8895830
J Virol. 2010 Mar;84(6):3004-15
20071589
Int Arch Allergy Immunol. 2007;143 Suppl 1:80-3
17541283
Virology. 2005 Oct 25;341(2):179-89
16095644
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Feb 1;65(Pt 2):163-5
19194011
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
7984417
Virology. 2005 Feb 5;332(1):406-17
15661171
J Virol. 2007 Dec;81(24):13469-77
17928350
Curr Opin Immunol. 2008 Feb;20(1):17-22
18272355
Acta Crystallogr D Biol Crystallogr. 2006 Apr;62(Pt 4):439-50
16552146
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
15299374
J Virol. 2005 Dec;79(23):14876-86
16282487
Curr Opin Immunol. 2007 Feb;19(1):17-23
17118636
J Virol. 2006 Jun;80(11):5168-78
16698997
PLoS One. 2008;3(12):e3965
19115016
Expert Rev Mol Med. 2004 Sep 21;6(20):1-24
15383160
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
15299926
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83
17452350
Acta Crystallogr D Biol Crystallogr. 1993 Jan 1;49(Pt 1):129-47
15299554
Methods Mol Biol. 2004;278:313-52
15318002
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):314-9
20018665
Nat Struct Mol Biol. 2010 Feb;17(2):165-72
20081868
J Virol. 2006 Jul;80(13):6430-40
16775331
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):411-6
19122151
J Immunol. 2005 Sep 1;175(5):2851-8
16116171
J Virol. 2003 Jul;77(14):7945-56
12829834
J Infect Dis. 2007 Nov 15;196 Suppl 2:S438-43
17940981
Int J Biochem Cell Biol. 2005 Aug;37(8):1560-6
15896665
J Virol. 2008 Mar;82(6):2699-704
18199658
J Biomol NMR. 1995 Nov;6(3):277-93
8520220
J Virol. 2008 Jun;82(11):5348-58
18353943
Virology. 2009 Sep 15;392(1):11-5
19628240
J Virol. 2008 Jul;82(13):6190-9
18417588
Mol Cell. 2002 Aug;10(2):307-16
12191476
Virology. 2004 Oct 25;328(2):177-84
15464838
Science. 2009 Jul 10;325(5937):204-6
19590002
Acta Crystallogr D Biol Crystallogr. 1997 Jul 1;53(Pt 4):448-55
15299911
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):545-51
17683970
J Virol. 2002 May;76(10):4855-65
11967302
J Virol. 2006 Jun;80(11):5156-67
16698996
J Virol. 2006 Mar;80(6):3009-20
16501110
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1373-82
11567148
J Biomol Screen. 2006 Oct;11(7):854-63
16943390
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
15572765
Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8
17610952
J Virol. 2007 Jan;81(1):182-92
17065211
Euro Surveill. 2009 Jan 29;14(4):
19215709
PLoS Pathog. 2007 Jun;3(6):e86
17590081
Biochimie. 2007 Jun-Jul;89(6-7):754-60
17379377
J Infect Dis. 2007 Nov 15;196 Suppl 2:S247-50
17940956
Virol J. 2006 May 23;3:31
16719918